Takeovers refocus Sanofi on rare diseases
Interviewee/Contributor
Robin Davison
Organisation
New Science Global Healthcare Fund
Research Directory
How GMO rules affect gene and cell therapies
Interviewee/ContributorHouria BachtarziOrganisationERA Consulting (UK) LtdThe advance of digital medicine
Interviewee/ContributorJean-Claude MullerOrganisationMedNousRemotely controlling gene expression
Interviewee/ContributorMartin FusseneggerOrganisationETH ZürichPixium Vision: A strategy for treating macular degeneration
Interviewee/ContributorKhalid IshaqueOrganisationPixium Vision SAThe impact of digital technology on diagnostics
Interviewee/ContributorJohn LinOrganisationGE HealthcareMedNous Briefing: FDA policy on digital health
Interviewee/ContributorPeter CharlishOrganisationMedNousThe case for optimism for Europe's biotech sector
Interviewee/ContributorRobin DavisonOrganisationNew Science Global Healthcare FundOrchard Therapeutics targets rare diseases
Interviewee/ContributorMark RotheraOrganisationOrchard TherapeuticsThe three waves of gene therapy
Interviewee/ContributorFrank SchniedersOrganisationProvecs Medical GmbH